Revolution Medicines reported data for its experimental drug daraxonrasib in pancreatic cancer at the ASCO conference, marking what researchers describe as a paradigm shift in treating this aggressive malignancy. The trial results address a tumor type that has seen few therapeutic advances in decades.
The study, focusing on patients with KRAS G12D-mutated pancreatic cancer, achieved efficacy rates described as “unprecedented” by investigators. While specific numerical figures were not disclosed in available reports, the response rates and survival metrics prompted excitement among oncologists. The safety profile appeared manageable, though detailed adverse event data remains under review.
Revolution plans to discuss these findings with the FDA to determine a regulatory pathway, potentially including accelerated approval. The company has not yet announced a PDUFA date, but analysts expect a filing later this year if confirmatory data hold. The drug's mechanism targets a specific KRAS mutation found in about 40% of pancreatic cancers.
Investor reaction was positive, driving Revolution's stock up in after-hours trading. The global pancreatic cancer drug market, expected to exceed $5 billion by 2030, could see daraxonrasib capture significant share if approved. Competitors include Amgen's Lumakras and Mirati's Krazati, though neither has shown similar efficacy in this indication.
Clinicians caution that longer follow-up is needed to confirm durability of responses. Some experts note that prior KRAS inhibitors have faced resistance development, which could limit daraxonrasib's long-term benefit. Patient advocacy groups emphasize that even modest survival gains would be meaningful given current treatment options.